Dominic Tilden is a health economist with 20 years practical experience in the design, development and implementation of health economic evaluations. The health economic evaluations have taken the form of cost-minimisation, cost- effectiveness, cost-utility and cost-benefit analyses. This experience has been gained across a large variety of therapeutic areas including oncology, cardiovascular diseases, diabetes, schizophrenia, ADHD, infectious diseases, osteoarthritis, thrombosis, transplantation, diagnostics and screening.
Dominic Tilden has been an integral component of teams developing reimbursement applications across the world. He has developed and implemented creative and analytical strategies, managed multi-disciplinary teams and prepared submission dossiers for the communication of sound health technology assessment and health economic arguments to reimbursement authorities in Australia, England, Wales, Scotland and many European countries. Since 1999, Dominic has been involved in and/or responsible for: over 200 submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia; over 6 submissions to the National Institute for Health and clinical Excellence (NICE) in England and Wales and more than 5 submissions to the Scottish Medicines Consortium (SMC). Health economic evaluations completed by Dominic Tilden have been used in reimbursement applications in Canada, Finland, France, Germany, Holland, Norway, Portugal, Sweden and more.
Dominic has developed models using first and second order Monte Carlo simulation, discrete event `simulation, decision-analytic models, Markov and semi-Markov models and probabilistic. These models are developed in DATA software (by TreeAge) or with advanced Excel skills including visual basic (if necessary). Dominic has been previously employed by TreeAge software as a trainer for their DATA software training courses.
Dr Suzi Cottrell is highly experienced in the use and application of health technology assessment methodologies, including systematic review, meta-analysis, patient preference using discrete choice experiment, health state utility valuation, conduct of health-related quality of life studies and other qualitative/quantitative health care research. Suzi has contributed to numerous reimbursement applications for drugs, medical devices and diagnostic tests both in Australia and New Zealand as well as the UK and several other European countries. Her experience covers many therapeutic areas including: mental health, oncology, infectious diseases, cardiovascular disease, type 2 diabetes, rheumatoid arthritis, psoriasis and asthma.
In her previous role, Suzi worked as a senior consultant and manager in health economics and outcomes research in the UK. Formerly, she was engaged in toxicology research and chemical/drug safety assessment, within both academic and pharmaceutical industry settings, and for the UK Department of Health. She graduated with an honours degree in biochemistry from the University of Surrey, where she also completed her PhD studies in xenobiotic metabolism. Suzi took up her position at THEMA in 2008.
Through her career in health technology assessment, Mia has worked on a wide variety of projects for the pharmaceutical industry and regulatory bodies. She has been involved in several major reimbursement applications for Australia and overseas. Mia has also been involved in evaluating applications on behalf of the Medical Services Advisory Committee (MSAC). Mia’s particular interest is in the area of systematic review and meta-analysis (direct and indirect). Mia graduated in 2002 with a Bachelor of Applied Science (Exercise and Sports Science) from the University of Sydney. After graduating, Mia began a career as a health outcomes analyst in a health economic and outcomes research consultancy firm. Mia joined THEMA in April 2007 and in conjunction with this she undertaking a Master of Medical Science (Clinical Epidemiology and Pharmacoeconomics specialisation) degree at the University of Newcastle. Mia joined THEMA in 2007.
At THEMA, Dan applies his considerable technical expertise and interest in decision analytic modelling, economic evaluation and health care reimbursement to a wide range of projects. Dan has over 15 years’ experience in conducting economic evaluations of new health technologies in a wide range of therapeutic areas, and has worked in health economic consulting companies in both Australia and the UK. He has experience in preparing reimbursement submissions for Australia, New Zealand, and the UK.
Dan graduated from the University of Sydney with a degree in economics, majoring in economics and econometrics. Dan joined THEMA Consulting in 2009.
Nimita joined THEMA in December 2012 as Senior Partner, Health Outcomes. She joined THEMA, having worked as a senior consultant and manager in health economics and outcomes research at Health Technology Analysts, and then OptumInsight since August 2007. Prior to this, Nimita worked as a Research Manager in the Sleep and Circadian Research Group of the Woolcock Institute for medical research. Nimita has contributed extensively to health economics and outcomes research projects on behalf of public sector organisations (e.g. New Zealand Ministry of Health and the Cancer Institute NSW), as well as pharmaceutical companies and device manufacturers. This includes managing the preparation of reimbursement applications for new drugs, diagnostic technologies, medical devices and co-dependent technologies, and managing the development of clinical practice guidelines for non-profit healthcare organisations. Her experience covers many therapeutic/disease areas including: mental health, cardiovascular disease, HIV, Alzheimer’s disease, enzyme deficiencies and oncology. Nimita is currently undertaking a Masters in Epidemiology at the London School of Hygiene and Tropical Medicine.
Koji's main focus at THEMA is formulation of market access and pricing strategies, market feasibility studies, preparation and evaluation of reimbursement applications, pricing assessment, and forecasting. Over the past 16 years, Koji has gained a sound understanding of reimbursement and pricing systems in Australia and overseas through a diverse range of health economics projects both as a consultant and in the health economics team of a global pharmaceutical company.
Koji has also worked as an evaluator of funding applications for new medical procedures on behalf of the Medical Services Advisory Committee for the Commonwealth Department of Health and Ageing. After completing a Master's degree in economics, Koji obtained a Graduate Certificate in Pharmacoeconomics from Monash University in 2006. Koji has been with THEMA since 2010.
Dr Meredith Edwards has worked for 10 years in healthcare consulting. She obtained her medical degree with honours in Australia, then worked as a doctor in both Australia and the UK where she gained experience in several clinical specialties. Meredith was then based in France where she was the Director of Medical Affairs in a Clinical Research Organisation before moving into the field of strategic and management consulting where she was involved in developing product launch plans, corporate strategy, drug approval regulatory strategy definition, expert interviews, clinical trial analysis, and hospital program and strategy formulation. Meredith then moved into the field of healthcare market access, pricing and reimbursement, where she worked as a Senior Consultant for 5 years. In this role she was based in France, the USA, and then Sydney, and was involved in authoring Global Value Dossiers and systematic reviews, aiding companies in strategy formulation, and was part of the internal quality control committee. She then joined THEMA as a Senior Partner in May 2014. Meredith has published several articles in both scientific and industry journals, and is currently completing a Masters of Public Health at the University of Sydney.
Matthew graduated from the University of Otago with a Bachelor of Science majoring in Neuroscience and Psychology before completing his Masters of Bioscience Enterprise and Research Commercialisation at the University of Auckland. After leaving university in 2010, Matthew worked as a Health Economics and Outcomes Research Analyst, and then Senior Analyst at a health technology assessment consultancy in Sydney. During this time, he worked on a number of PBAC, MSAC and co-dependent technology reimbursement submissions across a range of therapeutic areas including oncology (lung, breast), respiratory and cardiovascular medicine, infectious disease, endocrinology, and dermatology. In addition to his work in reimbursement and market access, Matthew has also contributed to a number of systematic reviews, white papers, global value dossiers, and strategy/feasibility briefs. He began working at THEMA in 2013.
Carmel is a Health Economics and Outcomes Researcher with experience in consulting companies in both Australia and the UK. She is knowledgeable in HTA reimbursement processes in Australia, Europe and North America and has experience in numerous market access activities including critical appraisal and evaluation of clinical and health economic evidence in literature, systematic review and meta-analyses, and the preparation of reimbursement applications. Her time at a UK health economic consultancy involved conducting strategic payer landscaping research in order to understand the factors that influence HTA decisions globally and to inform strategy to maximise reimbursement success. During her career, Carmel has worked a number of therapeutic areas including, oncology, obesity, cystic fibrosis, multiple sclerosis, acute coronary syndromes, major depression and asthma. Carmel graduated from the University of New South Wales with a double degree in Science majoring in Pharmacology, and Social Science majoring in Social Policy and Psychology. She has also completed a Master of Public Health from the University of Sydney. Carmel joined THEMA in 2013.
Keira has contributed to HTA reimbursement applications for new diagnostic technologies, new drugs and medical devices. She applies her knowledge of statistics, health technology assessment and systematic review methodologies to meta-analyses, utility valuations, critical appraisal of epidemiological studies and quantitative health care research. Her experience ranges across a variety of therapeutic areas including coronary heart disease, oncology, mental health and childhood vaccines. In addition, she has contributed to diagnostic technology assessments in respiratory health and the development of national guidelines for alcohol use in pregnancy.
Prior to joining THEMA, Keira worked as a biostatistician for the NSW Ministry of Health and the Australian Institute of Health Innovation.
She graduated with an honours degree in Molecular Microbiology from the University of Calgary, a Master of Science in Epidemiology from McGill University and a Graduate Diploma in Biostatistics from the University of Sydney.
Magda joined THEMA in 2016 to pursue her interest in health economics and outcomes research following the completion of a graduate diploma in Health economics and Policy at Monash University. Prior to joining THEMA, Magda worked as a genetic epidemiologist and held a research fellow position at the Centenary Institute and the University of Sydney. With eleven years’ experience in leading research both locally and overseas, she has extensive knowledge in the field of infectious diseases, human genetics, epidemiology and molecular biology.
Lara completed her Bachelor of Pharmacy (Honours Class I) at the University of Sydney in 2010 and has since gained extensive experience as a pharmacist. In 2015, Lara completed her Master of Public Health in Health Economic Evaluation at the University of New South Wales. To pursue her interest in health economics, Lara joined THEMA as an analyst in August 2016.
William graduated with a Masters of Commerce from the University of Sydney in 2016. Will joined THEMA in 2016 to pursue a career in health economics.